Abstract
Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease in western countries. A better understanding of the molecular mechanisms underlying NSCLC etiology, pathogenesis, and therapeutics will lead to improved clinical outcomes. Recent technological advances in gene expression profiling (in particular, with cDNA and oligonucleotide microarrays) allow the simultaneous analysis of the expression of thousands of genes. In this review, the technology of global gene expression profiling is discussed, and the progress made thus far with it in NSCLC is reviewed. A new molecular classification of NSCLC has been developed, which has provided important insights into etiology and pathogenesis. Other studies have found potential biomarkers for NSCLC that may be of use in diagnosis, screening, and assessing the effectiveness of therapy. Finally, advances have been made in the understanding of the molecular mechanisms of NSCLC progression and the molecular mechanisms of action of currently used cytotoxic drugs. This may facilitate the improvement of current therapeutics and the identification of novel targets. Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease.
| Original language | English |
|---|---|
| Pages (from-to) | 3237-3248 |
| Number of pages | 12 |
| Journal | Clinical Cancer Research |
| Volume | 10 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 15 May 2004 |
Keywords
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- DNA, Complementary
- Disease Progression
- Gene Expression Profiling
- Humans
- Lung Neoplasms
- Oligonucleotide Array Sequence Analysis
- Phenotype
- Prognosis
- Proteome
- RNA
- RNA, Messenger
- Tumor Markers, Biological
- Messenger-RNA Expression
- CDNA Microarray
- Anticancer Drugs
- Altered Expression
- Serial Analysis
- Adenocarcinoma
- Chemotherapy
- Sensitivity
- Prediction
- Carcinomas
Cite this
Gene expression profiling in non-small cell lung cancer : from molecular mechanisms to clinical application. / Petty, Russell D; Nicolson, Marianne C; Kerr, Keith M; Collie-Duguid, Elaina; Murray, Graeme I.
In: Clinical Cancer Research, Vol. 10, No. 10, 15.05.2004, p. 3237-3248.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Gene expression profiling in non-small cell lung cancer
T2 - from molecular mechanisms to clinical application
AU - Petty, Russell D
AU - Nicolson, Marianne C
AU - Kerr, Keith M
AU - Collie-Duguid, Elaina
AU - Murray, Graeme I
PY - 2004/5/15
Y1 - 2004/5/15
N2 - Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease in western countries. A better understanding of the molecular mechanisms underlying NSCLC etiology, pathogenesis, and therapeutics will lead to improved clinical outcomes. Recent technological advances in gene expression profiling (in particular, with cDNA and oligonucleotide microarrays) allow the simultaneous analysis of the expression of thousands of genes. In this review, the technology of global gene expression profiling is discussed, and the progress made thus far with it in NSCLC is reviewed. A new molecular classification of NSCLC has been developed, which has provided important insights into etiology and pathogenesis. Other studies have found potential biomarkers for NSCLC that may be of use in diagnosis, screening, and assessing the effectiveness of therapy. Finally, advances have been made in the understanding of the molecular mechanisms of NSCLC progression and the molecular mechanisms of action of currently used cytotoxic drugs. This may facilitate the improvement of current therapeutics and the identification of novel targets. Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease.
AB - Non-small cell lung cancer (NSCLC) is the most common cause of premature death from malignant disease in western countries. A better understanding of the molecular mechanisms underlying NSCLC etiology, pathogenesis, and therapeutics will lead to improved clinical outcomes. Recent technological advances in gene expression profiling (in particular, with cDNA and oligonucleotide microarrays) allow the simultaneous analysis of the expression of thousands of genes. In this review, the technology of global gene expression profiling is discussed, and the progress made thus far with it in NSCLC is reviewed. A new molecular classification of NSCLC has been developed, which has provided important insights into etiology and pathogenesis. Other studies have found potential biomarkers for NSCLC that may be of use in diagnosis, screening, and assessing the effectiveness of therapy. Finally, advances have been made in the understanding of the molecular mechanisms of NSCLC progression and the molecular mechanisms of action of currently used cytotoxic drugs. This may facilitate the improvement of current therapeutics and the identification of novel targets. Taken together, these advances hold the promise of an improved understanding of the molecular biology of NSCLC and its treatment, which in turn will lead to improved outcomes for this deadly disease.
KW - Carcinoma, Non-Small-Cell Lung
KW - Cell Line, Tumor
KW - DNA, Complementary
KW - Disease Progression
KW - Gene Expression Profiling
KW - Humans
KW - Lung Neoplasms
KW - Oligonucleotide Array Sequence Analysis
KW - Phenotype
KW - Prognosis
KW - Proteome
KW - RNA
KW - RNA, Messenger
KW - Tumor Markers, Biological
KW - Messenger-RNA Expression
KW - CDNA Microarray
KW - Anticancer Drugs
KW - Altered Expression
KW - Serial Analysis
KW - Adenocarcinoma
KW - Chemotherapy
KW - Sensitivity
KW - Prediction
KW - Carcinomas
U2 - 10.1158/1078-0432.CCR-03-0503
DO - 10.1158/1078-0432.CCR-03-0503
M3 - Article
VL - 10
SP - 3237
EP - 3248
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 10
ER -